Twin Peaks Wealth Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32	Closed	-$1.86K	–	2251
2026 Q1	$1.86K	Buy	+32	New	+$1.47K	﹤0.01%	1736
2025 Q3	–	Sell	-1	Closed	-$36	–	2177
2025 Q2	$36	Buy	+1	New	+$33	﹤0.01%	2210

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Twin Peaks Wealth Advisors's XENE Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 32 shares — an estimated $1.86K sold.

Twin Peaks Wealth Advisors first reported a position in XENE in Q2 2025 and held it in 2 quarters. The position peaked at $1.86K in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 32 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.86K.
Twin Peaks Wealth Advisors first reported a position in Xenon Pharmaceuticals in Q2 2025 and held it in 2 quarters.
Twin Peaks Wealth Advisors's Xenon Pharmaceuticals position peaked at $1.86K in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.